There is currently no strong evidence that additional immune therapy benefits patients with renal cell carcinoma who were treated in the advanced setting.

Immune checkpoint inhibitor-based combinations have become the preferred first-line therapy for patients with metastatic clear cell renal cell carcinoma, but more than a third of eligible patients do ...

Prostate-specific membrane antigen (PSMA) gene expression predicts angiogenesis and response to tyrosine kinase inhibitors (TKIs) in patients with metastatic clear cell renal cell carcinoma (RCC), ...

Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in ...

Cancer immunotherapy is a therapy used to treat ... with sustained tumoricidal activity as effective therapy against renal cell carcinoma. The immune response of immunotherapy in colorectal ...

At AUA 2025, experts will present on novel bladder cancer therapies, advanced renal cell carcinoma comparisons, frailty in ...

An artificial intelligence (AI)-based model developed by UT Southwestern Medical Center researchers can accurately predict ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...